Germany's Curetis Adds $6.4M to Series A Financing to Prep MDx System for US Trials

The trials, expected to begin in the second half of this year, will be for its benchtop automated DNA-testing platform and its first cartridge-based test for multiple causative agents of pneumonia and antibiotic-resistance markers.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.